Skip to main content
Login
Contact
Subscribe
Search form
Search
The Kane Republican
Home
Forms
News
Sports
Classifieds
Obituaries
Entertainment
Special Sections
Talking About...
Photos
Videos
Games
Community Links
KADC
Kane Area High School
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
Dow Jones Industrial Average
Nasdaq Composite
Standard & Poors 500
New York Composite
Gold
Crude Oil
Markets
Stocks
Funds
Tools
Overview
News
Currencies
International
Treasuries
Aclaris Therapts
(NQ:
ACRS
)
18.44
USD
UNCHANGED
Streaming Delayed Price
Updated: 6:07 AM EST, Jan 28, 2021
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All news about Aclaris Therapts
< Previous
1
2
3
4
5
6
7
8
9
...
19
20
Next >
Frazier Healthcare Partners Adds Highly Experienced Investor to Life Sciences Team
January 26, 2021
Frazier Healthcare Partners announced the planned addition of Albert Cha, M.D., Ph.D. as Managing Partner on the Life Sciences team. He has over 20 years of experience investing in public and private...
From
Business Wire News Releases
Gaining Ground After A Tough Couple Of Weeks
January 25, 2021
After a tumultuous start to the year, things have finally started to turn around in my day trading accounts. While it’s a low bar, ...
Tags
Warrior Trading
BBIG
Benzinga
From
Benzinga
12 Health Care Stocks Moving In Monday's Intraday Session
January 25, 2021
Gainers VYNE Therapeutics (NASDAQ:VYNE) shares moved upwards by 37.5% to $2.58 during Monday's regular session. ...
Tags
Market News
KMPH
Intraday Update
From
Benzinga
Investors Snag ACRS Even Cheaper Than Its Secondary Stock Offering
January 22, 2021
Looking back to 2 days ago, Aclaris Therapeutics Inc (ACRS) priced a 5,483,714 share secondary stock offering at $17.50 per share. Buyers in that offering made a considerable investment into the...
Tags
Stocks
From
Market News Video
The Daily Biotech Pulse: Addex Jumps On Positive Data For Out-Licensed Drug, COVID-19 Vaccine Developer Inovio Announces $150M Follow-On Offering, Boston Scientific Goes Shopping
January 21, 2021
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting ...
Tags
PACB
LMAT
BIVI
From
Benzinga
10 Biggest Price Target Changes For Wednesday
January 20, 2021
UBS boosted Netflix Inc (NASDAQ: NFLX) price target from $540 to $650. Netflix shares rose 13.6% to $570.03 in pre-market ...
Tags
NFLX
GBT
Benzinga
From
Benzinga
Aclaris Announces Pricing of Public Offering of Common Stock
January 20, 2021
From
GlobeNewswire News Releases
Aclaris Therapeutics Soars After Promising Study Against Rheumatoid Arthritis
January 20, 2021
During the trading day yesterday, Aclaris Therapeutics’ stock shot upwards with a rise of more than 200%.
Tags
Healthcare
Pharma/Biotech
Stocks / Equities
From
Blogs - TalkMarkets
The Daily Biotech Pulse: FDA Greenlights Merck's Heart Failure Drug, Histogen Hit With Clinical Hold, Aptorum Gets Nod For Commencing Human Study
January 20, 2021
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting ...
Tags
BNR
BLRX
MCRB
From
Benzinga
77 Biggest Movers From Yesterday
January 20, 2021
Gainers Gritstone Oncology, Inc. (NASDAQ: GRTS) shares jumped 248.5% to close at $22.27 on Tuesday after the company announced ...
Tags
BB
STIM
IDRA
From
Benzinga
Best Penny Stocks To Buy Right Now? 5 For Your January Watch List
January 19, 2021
Tags
Market News
From
Penny Stocks to Buy, Picks, News and Information | PennyStocks.com - Feed
Aclaris Announces Proposed Public Offering of Common Stock
January 19, 2021
From
GlobeNewswire News Releases
Mid-Afternoon Market Update: Nasdaq Surges 1.5%; Aclaris Therapeutics Shares Spike Higher
January 19, 2021
Toward the end of trading Tuesday, the Dow traded up 0.42% to 30,944.82 while the NASDAQ rose 1.50% to 13,193.24. The S&P also rose, ...
Tags
Eurozone
Commodities
Earnings
From
Benzinga
Why Aclaris Therapeutics Stock Skyrocketed More Than 200% Today
January 19, 2021
Investors are excited about the biotech's clinical trial results.
Tags
ACRS
Market News
From
Motley Fool
12 Health Care Stocks Moving In Tuesday's Intraday Session
January 19, 2021
Gainers Aclaris Therapeutics (NASDAQ:ACRS) shares rose 194.21% to $17.3 during Tuesday's regular session. Trading ...
Tags
YTEN
Market News
PRPH
From
Benzinga
Mid-Day Market Update: Crude Oil Rises Over 1%; ProPhase Labs Shares Plummet
January 19, 2021
Midway through trading Tuesday, the Dow traded up 0.36% to 30,924.60 while the NASDAQ rose 0.84% to 13,108.03. The S&P also rose, ...
Tags
TELL
Global
Penny Stocks
From
Benzinga
50 Stocks Moving In Tuesday's Mid-Day Session
January 19, 2021
Gainers Aclaris Therapeutics, Inc. (NASDAQ: ACRS) shares climbed 164.3% to $15.54 after the company reported positive preliminary ...
Tags
EH
LAC
IZEA
From
Benzinga
ACRS Stock Alert: Why Aclaris Therapeutics Is Up Over 200% Today
January 19, 2021
<p><a rel="nofollow" href="https://investorplace.com">InvestorPlace - Stock Market News, Stock Advice & Trading Tips</a></p> <p>Aclaris Therapeutics (ACRS) stock is soaring higher on Tuesday after...
Tags
Today's Market
Market News
ACRS
From
InvestorPlace
Why Aclaris, Tenax, Gritstone, Merus, Minerva And Celyad Are Rallying Today
January 19, 2021
A slew of biopharma stocks are making big moves Tuesday on the back of clinical trial readouts as well announcements regarding M&A ...
Tags
Health Care
News
ACRS
From
Benzinga
Mid-Morning Market Update: Markets Open Higher; Goldman Sachs Earnings Top Views
January 19, 2021
Following the market opening Tuesday, the Dow traded up 0.32% to 30,914.29 while the NASDAQ rose 0.90% to 13,114.92. The S&P also ...
Tags
Earnings
Commodities
Eurozone
From
Benzinga
12 Health Care Stocks Moving In Tuesday's Pre-Market Session
January 19, 2021
Gainers Tenax Therapeutics (NASDAQ:TENX) shares moved upwards by 75.28% to $3.12 during Tuesday's pre-market ...
Tags
TENX
BHVN
Movers
From
Benzinga
Aclaris Therapeutics Announces Positive Preliminary Topline Data from 12-Week Phase 2a Trial of Oral ATI-450 for Moderate to Severe Rheumatoid Arthritis
January 19, 2021
From
GlobeNewswire News Releases
The Daily Biotech Pulse: FDA Nod For Amphastar's Generic Glucagon, Arcturus Sinks On Vaccine Data, Decision Day For Osmotica
December 29, 2020
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting ...
Tags
EW
SPRO
VCEL
From
Benzinga
Stocks That Hit 52-Week Highs On Monday
December 28, 2020
This morning 301 companies reached new 52-week highs. Significant Points: The largest company by market cap to break ...
Tags
Semiconductors
FLEX
NOVA
From
Benzinga
12 Health Care Stocks Moving In Wednesday's After-Market Session
December 23, 2020
Gainers Bellicum Pharmaceuticals (NASDAQ:BLCM) shares rose 9.91% to $4.1 during Wednesday's after-market session. Trading volume ...
Tags
ALT
Market News
VIR
From
Benzinga
The Daily Biotech Pulse: Supernus Issues Positive ADHD Readout, Sorrento Files For Emergency Use Authorization For Rapid COVID-19 Test, Inhibikase To Make Wall Street Debut
December 23, 2020
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting ...
Tags
SMTI
NK
STIM
From
Benzinga
Stocks That Hit 52-Week Highs On Tuesday
December 22, 2020
During Tuesday's morning session, 342 companies made new 52-week highs. Intriguing Points: The largest company by ...
Tags
BSET
OXFD
PCTY
From
Benzinga
First Week of ACRS August 2021 Options Trading
December 18, 2020
Investors in Aclaris Therapeutics Inc (ACRS) saw new options begin trading this week, for the August 2021 expiration. One of the key data points that goes into the price an option buyer is willing to...
Tags
Stocks
From
Market News Video
Thinking about buying stock in MacroGenics, Arbutus Biopharma, Riot Blockchain, Aclaris Therapeutics, or Myovant Sciences?
December 17, 2020
InvestorsObserver issues critical PriceWatch Alerts for MGNX, ABUS, RIOT, ACRS, and MYOV.
From
PR Newswire
Aclaris Therapeutics Reaches Analyst Target Price
December 17, 2020
In recent trading, shares of Aclaris Therapeutics Inc (ACRS) have crossed above the average analyst 12-month target price of $4.83, changing hands for $5.01/share. When a stock reaches the target an...
Tags
ETFs
From
ETF Channel
< Previous
1
2
3
4
5
6
7
8
9
...
19
20
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.